Thagaards Fodterapi ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
Bankruptcy risk for industry  0.8% 0.8% 0.8% 0.8% 0.8%  
Bankruptcy risk  3.8% 4.8% 3.4% 4.3% 3.6%  
Credit score (0-100)  51 44 53 47 52  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  -0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9

Net sales  0 0 0 0 0  
Gross profit  10.6 184 224 213 253  
EBITDA  -3.1 113 -17.0 -94.6 -9.7  
EBIT  -11.9 104 -25.7 -103 -18.5  
Pre-tax profit (PTP)  -11.9 104.2 -26.3 -103.6 -18.7  
Net earnings  -11.9 84.2 -24.1 -81.9 -15.9  
Pre-tax profit without non-rec. items  -11.9 104 -26.3 -104 -18.7  

 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9

Tangible assets total  57.5 48.7 39.9 31.1 22.4  
Shareholders equity total  -19.8 64.4 75.3 -6.6 -22.5  
Interest-bearing liabilities  103 108 30.8 85.8 103  
Balance sheet total (assets)  89.6 202 121 116 102  

Net Debt  76.9 -40.6 -40.5 41.1 61.6  
 
See the entire balance sheet

Volume 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  10.6 184 224 213 253  
Gross profit growth  0.0% 1,633.3% 21.8% -4.8% 18.5%  
Employees  1 1 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  90 202 121 116 102  
Balance sheet change%  -5.3% 125.4% -40.0% -4.3% -11.9%  
Added value  -3.1 113.0 -17.0 -94.6 -9.7  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -18 -18 -18 -18 -18  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -2.0 1.0 -1.0 -2.0 -3.0  

Profitability 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  -111.7% 56.6% -11.5% -48.5% -7.3%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -11.2% 66.9% -15.9% -84.7% -14.9%  
ROI %  -11.6% 75.9% -18.5% -107.8% -19.6%  
ROE %  -12.9% 109.4% -34.5% -85.6% -14.5%  

Solidity 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
Equity ratio %  -18.1% 31.9% 62.1% -5.4% -18.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -2,497.7% -35.9% 239.0% -43.4% -633.7%  
Gearing %  -517.2% 167.1% 40.9% -1,293.8% -456.4%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.9% 0.4% 0.2%  

Liquidity 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
Quick Ratio  0.3 1.1 1.6 0.6 0.6  
Current Ratio  0.3 1.1 1.8 0.7 0.6  
Cash and cash equivalent  25.7 148.1 71.3 44.7 41.2  

Capital use efficiency 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -77.3 15.9 35.4 -37.8 -44.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
2024
2024/9
Net sales / employee  0 0 0 0 0  
Added value / employee  -3 113 -17 -95 -10  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -3 113 -17 -95 -10  
EBIT / employee  -12 104 -26 -103 -19  
Net earnings / employee  -12 84 -24 -82 -16